{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:11:06Z","timestamp":1790392266775,"version":"4.1.0"},"reference-count":47,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,28]]},"DOI":"10.20945\/2359-4292-2023-0416","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:23:17Z","timestamp":1724944997000},"source":"Crossref","is-referenced-by-count":11,"title":["GDF-15 levels in patients with polycystic ovary syndrome treated with metformin: a combined clinical and in silico pathway analysis"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9055-6523","authenticated-orcid":false,"given":"Fernanda M. V.","family":"Magalh\u00e3es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-9726","authenticated-orcid":false,"given":"Rodrigo M. C.","family":"Pestana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-6821","authenticated-orcid":false,"given":"Cl\u00e1udia N.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-2632","authenticated-orcid":false,"given":"Ieda F. O.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-2319","authenticated-orcid":false,"given":"Ana L.","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-7781","authenticated-orcid":false,"given":"Fl\u00e1via R.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-7472","authenticated-orcid":false,"given":"Fernando M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-2063","authenticated-orcid":false,"given":"Karina B.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20240829104515_B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","article-title":"Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy","volume":"182","author":"Patel","year":"2018","unstructured":"1. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27-36. doi: 10.1016\/j.jsbmb.2018.04.008.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"key20240829104515_B2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi","year":"2011","unstructured":"2. Goodarzi M, Dumesic D, Chazenbalk G, Azzizz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4): 219-31. doi: 10.1038\/nrendo.2010.217.","journal-title":"Nat Rev Endocrinol"},{"key":"key20240829104515_B3","article-title":"Polycystic ovary syndrome: current status and future perspective","volume":"6","author":"Barthelmess","year":"2014","unstructured":"3. Barthelmess E, Naz R. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014;6:104. doi: 10.2741\/e695.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"3","key":"key20240829104515_B4","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","unstructured":"4. Hoeger K, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071-83. doi: 10.1210\/clinem\/dgaa839.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20240829104515_B5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.0001-6349.2004.00373.x","article-title":"Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS","volume":"83","author":"Vanky","year":"2004","unstructured":"5. Vanky E, Kj\u00f8tr\u00f8d S, Salvesen K, Romundstad P, Moen M, Carlsen S. Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS. Acta Obstet Gynecol Scand. 2004;83(5):482-6. doi: 10.1111\/j.0001-6349.2004.00373.x.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"key20240829104515_B6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/0974-1208.86080","article-title":"Ovarian hyperstimulation syndrome","volume":"4","author":"Kumar","year":"2011","unstructured":"6. Kumar P, Sait S, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4(2):70-5. doi: 10.4103\/0974-1208.86080.","journal-title":"J Hum Reprod Sci"},{"issue":"1","key":"key20240829104515_B7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsmc.2007.11.001","article-title":"Polycystic Ovary Syndrome and Obstructive Sleep Apnea","volume":"3","author":"Tasali","year":"2008","unstructured":"7. Tasali E, Cauter E, Ehrmann D. Polycystic Ovary Syndrome and Obstructive Sleep Apnea. Sleep Med Clin. 2008;3(1):37-46. doi: 10.1016\/j.jsmc.2007.11.001.","journal-title":"Sleep Med Clin"},{"key":"key20240829104515_B8","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","unstructured":"8. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. doi: 10.1186\/1741-7015-8-41.","journal-title":"BMC Med"},{"issue":"8","key":"key20240829104515_B9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084110","article-title":"Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism","volume":"23","author":"Armanini","year":"2022","unstructured":"9. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. doi: 10.3390\/ijms23084110.","journal-title":"Int J Mol Sci"},{"key":"key20240829104515_B10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S0004-27302006000200014","article-title":"S\u00edndrome dos ov\u00e1rios polic\u00edsticos, s\u00edndrome metab\u00f3lica, risco cardiovascular e o papel dos agentes sensibilizadores da insulina","volume":"50","author":"Silva","year":"2006","unstructured":"10. Silva R, Pardini D, Kater C. S\u00edndrome dos ov\u00e1rios polic\u00edsticos, s\u00edndrome metab\u00f3lica, risco cardiovascular e o papel dos agentes sensibilizadores da insulina. Arq Bras Endocrinol Metabol. 2006;50:281-90. doi: 10.1590\/s0004-27302006000200014.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"key20240829104515_B11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.fertnstert.2011.11.023","article-title":"Is PCOS an inflammatory process?","volume":"97","author":"Duleba","year":"2012","unstructured":"11. Duleba A, Dokras A. Is PCOS an inflammatory process? Fertil Steril. 2012;97(1):7-12. doi: 10.1016\/j.fertnstert.2011.11.023.","journal-title":"Fertil Steril"},{"key":"key20240829104515_B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155187","article-title":"The hallmark of pro- and anti-inflamatory cytokine ratios in women with polycystic ovary syndrome","volume":"134","author":"Tosatti","year":"2020","unstructured":"12. Tosatti J, S\u00f3ter M, Ferreira C, Silva I, C\u00e2ndido A, Sousa M, et al. The hallmark of pro- and anti-inflamatory cytokine ratios in women with polycystic ovary syndrome. Cytokine. 2020;134:155187. doi: 10.1016\/j.cyto.2020.155187.","journal-title":"Cytokine"},{"key":"key20240829104515_B13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","unstructured":"13. Wischhusen J, Melero I, Fridman W. Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951. doi: 10.3389\/fimmu.2020.00951.","journal-title":"Front Immunol"},{"issue":"16","key":"key20240829104515_B14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168889","article-title":"GDF15 and cardiac cells: current concepts and new insights","volume":"22","author":"Rochette","year":"2021","unstructured":"14. Rochette L, Dogon G, Zeller M. GDF15 and cardiac cells: current concepts and new insights. Int J Mol Sci. 2021;22(16):8889. doi: 10.3390\/ijms22168889.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"key20240829104515_B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","article-title":"The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases","volume":"28","author":"Tsai","year":"2018","unstructured":"15. Tsai V, Husaini Y, Sainsbury, Brown D, Breit S. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353-68. doi: 10.1016\/j.cmet.2018.07.018.","journal-title":"Cell Metab"},{"issue":"21","key":"key20240829104515_B16","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u00df superfamily","volume":"94","author":"Bootcov","year":"1997","unstructured":"16. Bootcov M, Bauskin A, Valenzuela S, Moore A, Bansal A, Zhang H, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u00df superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514-9. doi: 10.1073\/pnas.94.21.11514.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"key20240829104515_B17","first-page":"494","article-title":"GDF-15 as a Biomarker in Cardiovascular Disease","volume":"116","author":"May","year":"2021","unstructured":"17. May B, Pimentel M, Zimerman L, Rohde L. GDF-15 as a Biomarker in Cardiovascular Disease. Arq Bras Cardiol. 2021;116(3):494-500. doi: 10.36660\/abc.20200426.","journal-title":"Arq Bras Cardiol"},{"key":"key20240829104515_B18","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/490842","article-title":"GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective","volume":"2015","author":"Adela","year":"2015","unstructured":"18. Adela R, Banerjee S. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015.490842. doi: 10.1155\/2015\/490842.","journal-title":"J Diabetes Res"},{"key":"key20240829104515_B19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00191","article-title":"Metmorfin and Its Benefits for Various Diseases","volume":"11","author":"Lv","year":"2020","unstructured":"19. Lv Z, Guo Y. Metmorfin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). 2020;11:191. doi: 10.3389\/fendo.2020.00191.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20240829104515_B20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09189-y","article-title":"Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems","volume":"7","author":"Udhane","year":"2017","unstructured":"20. Udhane S. Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems. Sci Rep. 2017;7:8652. doi: 10.1038\/s41598-017-09189-y.","journal-title":"Sci Rep"},{"key":"key20240829104515_B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112582","article-title":"GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease","volume":"146","author":"Xiao","year":"2022","unstructured":"21. Xiao QA, He Q, Zeng J, Xia X. GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease. Biomed Pharmacother. 2022;146:112582. doi: 10.1016\/j.biopha.2021.112582.","journal-title":"Biomed Pharmacother"},{"issue":"7795","key":"key20240829104515_B22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","unstructured":"22. Coll A, Chen M, Taskar P, Rimmington D, Patel S, Tadross J, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444-8. doi: 10.1038\/s41586-019-1911-y.","journal-title":"Nature"},{"issue":"2","key":"key20240829104515_B23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/S0004-27302006000200016","article-title":"Cytokines, endothelial dysfunction, and insulin resistance","volume":"50","author":"Carvalho","year":"2006","unstructured":"23. de Carvalho M, Cola\u00e7o A, Fortes Z. Cytokines, endothelial dysfunction, and insulin resistance. Arq Bras Endocrinol Metabol. 2006;50(2):304-12. doi: 10.1590\/s0004-27302006000200016.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"5","key":"key20240829104515_B24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cmet.2023.03.014","article-title":"Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight","volume":"35","author":"Zhang","year":"2023","unstructured":"24. Zhang S, Bruce K, Danaei Z, Li RJW, Barros DR, Kuah R, et al. Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. Cell Metab. 2023; 35(5):875-86.e5. doi: 10.1016\/j.cmet.2023.03.014.","journal-title":"Cell Metab"},{"issue":"9","key":"key20240829104515_B25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00125-019-4913-2","article-title":"The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study","volume":"62","author":"Au Yeung","year":"2019","unstructured":"25. Au Yeung S, Luo S, Schooling C. The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. Diabetologia. 2019;62(9):1638-46. doi: 10.1007\/s00125-019-4913-2.","journal-title":"Diabetologia"},{"issue":"2","key":"key20240829104515_B26","first-page":"89","article-title":"Plasma GDF-15 levels and their association with hormonal and metabolic status in women with polycystic ovary syndrome aged 25-35","volume":"39","author":"Berberoglu","year":"2014","unstructured":"26. Berberoglu Z, Aktas A, Fidan Y, Yazici A, Aral Y. Plasma GDF-15 levels and their association with hormonal and metabolic status in women with polycystic ovary syndrome aged 25-35. Minerva Endocrinol. 2014;39(2):89-97.","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"key20240829104515_B27","article-title":"The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat","volume":"11","author":"Zegher","year":"2021","unstructured":"27. De Zegher F, D\u00edaz M, Villarroya J, Cair\u00f3 M, L\u00f3pez-Bermejo A, Villarroya F, et al. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep. 2021;11(1):7018. doi: 10.1038\/s41598-021-86317-9.","journal-title":"Sci Rep"},{"issue":"1","key":"key20240829104515_B28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"28. Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. doi: 10.1016\/j.fertnstert.2003.10.004.","journal-title":"Fertil Steril"},{"issue":"10","key":"key20240829104515_B29","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/a-1157-0615","article-title":"Effects of short term metformin treatment on brown adipose tissue activity and plasma irisin levels in women with polycystic ovary syndrome: A randomized controlled trial","volume":"52","author":"Oliveira","year":"2020","unstructured":"29. Oliveira F, Mamede M, Bizzi M, Rocha A, Ferreira C, Gomes K, et al. Effects of short term metformin treatment on brown adipose tissue activity and plasma irisin levels in women with polycystic ovary syndrome: A randomized controlled trial. Horm Metab Res. 2020;52(10):718-23. doi: 10.1055\/a-1157-0615.","journal-title":"Horm Metab Res"},{"key":"key20240829104515_B30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.988767","article-title":"Arachidonic Acid in Follicular Fluid of PCOS Induces Oxidative Stress in a Human Ovarian Granulosa Tumor Cell Line (KGN) and Upregulates GDF15 Expression as a Response","volume":"13","author":"Ma","year":"2022","unstructured":"30. Ma Y, Zheng L, Wang Y, Gao Y, Xu Y. Arachidonic Acid in Follicular Fluid of PCOS Induces Oxidative Stress in a Human Ovarian Granulosa Tumor Cell Line (KGN) and Upregulates GDF15 Expression as a Response. Front Endocrinol (Lausanne). 2022;13:865748. doi: 10.3389\/fendo.2022.865748.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"key20240829104515_B31","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-021-01463-3","article-title":"Regulation of circulating CTRP-2\/CTRP-9 and GDF-8\/GDF-15 by intralipids and insulin in healthy control and polycystic ovary syndrome women following chronic exercise training","volume":"20","author":"Jerobin","year":"2021","unstructured":"31. Jerobin J, Ramanjaneya M, Bettahi I, Parammal R, Siveen K, Alkasem M, et al. Regulation of circulating CTRP-2\/CTRP-9 and GDF-8\/GDF-15 by intralipids and insulin in healthy control and polycystic ovary syndrome women following chronic exercise training. Lipids Health Dis. 2021;20(1):34. doi: 10.1186\/s12944-021-01463-3.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"key20240829104515_B32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00774-013-0560-8","article-title":"Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome","volume":"33","author":"Berberoglu","year":"2015","unstructured":"32. Berberoglu Z, Aktas A, Fidan Y, Yazici A, Aral Y. Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome. J Bone Miner Metab. 2015;33(1):101-8. doi: 10.1007\/s00774-013-0560-8.","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"key20240829104515_B33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","article-title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease","volume":"17","author":"Wang","year":"2021","unstructured":"33. Wang D, Day E, Townsend L, Djordjevic D, Jorgensen S, Steinberg G. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592-607. doi: 10.1038\/s41574-021-00529-7.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"key20240829104515_B34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","article-title":"Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss","volume":"1","author":"Day","year":"2019","unstructured":"34. Day E, Ford R, Smith B, Mohammadi-Shemirani P, Morrow M, Gutgesell R, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202-8. doi: 10.1038\/s42255-019-0146-4.","journal-title":"Nat Metab"},{"issue":"5","key":"key20240829104515_B35","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","article-title":"GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance","volume":"178","author":"Luan","year":"2019","unstructured":"35. Luan H, Wang A, Hilliard B, Carvalho F, Rosen C, Ahasic A, et al. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell. 2019;178(5):1231-1244.e11. doi: 10.1016\/j.cell.2019.07.033.","journal-title":"Cell"},{"issue":"2","key":"key20240829104515_B36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc16-1682","article-title":"Growth differentiation factor 15 as a novel biomarker for metformin","volume":"40","author":"Gerstein","year":"2017","unstructured":"36. Gerstein H, Pare G, Hess S, Ford R, Sjaarda J Raman K, et al. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care. 2017;40(2):280-3. doi: 10.2337\/dc16-1682.","journal-title":"Diabetes Care"},{"issue":"12","key":"key20240829104515_B37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/1753-0407.13334","article-title":"Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure","volume":"14","author":"Al-Kuraishy","year":"2022","unstructured":"37. Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Nadwa E, Albogami S, et al. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure. J Diabetes. 2022;14(12):806-14. doi: 10.1111\/1753-0407.13334.","journal-title":"J Diabetes"},{"issue":"16","key":"key20240829104515_B38","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14535","article-title":"Effect of menopausal hormone therapy on proteins associated with senescence and inflammation","volume":"8","author":"Faubion","year":"2020","unstructured":"38. Faubion L, White T, Peterson B, Geske J, LeBrasseur N, Schafer M, et al. Effect of menopausal hormone therapy on proteins associated with senescence and inflammation. Physiol Rep. 2020;8(16):e14535. doi: 10.14814\/phy2.14535.","journal-title":"Physiol Rep"},{"issue":"8","key":"key20240829104515_B39","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10815-018-1230-5","article-title":"Presence of growth\/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes","volume":"35","author":"Soucek","year":"2018","unstructured":"39. Soucek K, Malenovsk\u00e1 A, Kahounov\u00e1 Z, Remsik J, Holubcov\u00e1 Z, Soukup T, et al. Presence of growth\/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes. J Assist Reprod Genet. 2018;35(8):1407-17. doi: 10.1007\/s10815-018-1230-5.","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"key20240829104515_B40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38148-7","article-title":"Identification of biomarkers for glycaemic deterioration in type 2 diabetes","volume":"14","author":"Slieker","year":"2023","unstructured":"40. Slieker R, Donnelly L, Akalestou E, Lopez-Noriega L, Melhem R, G\u00fcnes A, et al. Identification of biomarkers for glycaemic deterioration in type 2 diabetes. Nat Commun. 2023;14(1):2533. doi: 10.1038\/s41467-023-38148-7.","journal-title":"Nat Commun"},{"issue":"1","key":"key20240829104515_B41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03998-z","article-title":"Reduced oxidative capacity in macrophages results in systemic insulin resistance","volume":"9","author":"Jung","year":"2018","unstructured":"41. Jung S, Choi M, Ryu D, Yi H, Lee S, Chang J, et al. Reduced oxidative capacity in macrophages results in systemic insulin resistance. Nat Commun. 2018;9(1):1551. doi: 10.1038\/s41467-018-03998-z.","journal-title":"Nat Commun"},{"issue":"11","key":"key20240829104515_B42","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.2337\/db17-0333","article-title":"Growth Differentiation Factor 15 Mediates Systemic Glucose Regulatory Action of T-Helper Type 2 Cytokines","volume":"66","author":"Lee","year":"2017","unstructured":"42. Lee S, Kang S, Choi M, Jung S, Ryu M, Chung H, et al. Growth Differentiation Factor 15 Mediates Systemic Glucose Regulatory Action of T-Helper Type 2 Cytokines. Diabetes. 2017;66(11):2774-88. doi: 10.2337\/db17-0333.","journal-title":"Diabetes"},{"key":"key20240829104515_B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121142","article-title":"NAG-1\/GDF15 inhibits diabetic nephropathy via inhibiting AGE\/RAGE-mediated inflammation signaling pathways in C57BL\/6 mice and HK-2 cells","volume":"311","author":"Chen","year":"2022","unstructured":"43. Chen J, Peng H, Chen C, Wang Y, Sang T, Cai Z, et al. NAG-1\/GDF15 inhibits diabetic nephropathy via inhibiting AGE\/RAGE-mediated inflammation signaling pathways in C57BL\/6 mice and HK-2 cells. Life Sci. 2022;311(Pt A):121142. doi: 10.1016\/j.lfs.2022.121142.","journal-title":"Life Sci"},{"issue":"4","key":"key20240829104515_B44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02601060221099716","article-title":"Prognostic value of circulating macrophage inhibitory cytokine 1-growth differentiation factor 15 (MIC-1\/GDF15) in obesity: Relation with vascular endothelial growth factor (VEGF) and markers of oxidative stress","volume":"29","author":"Parvaneh","year":"2023","unstructured":"44. Parvaneh R, Vajdi M, Shiraz A, Khani M, Farshbaf S, Farhangi M. Prognostic value of circulating macrophage inhibitory cytokine 1-growth differentiation factor 15 (MIC-1\/GDF15) in obesity: Relation with vascular endothelial growth factor (VEGF) and markers of oxidative stress. Nutr Health. 2023;29(4):707-13. doi: 10.1177\/02601060221099716.","journal-title":"Nutr Health"},{"issue":"12","key":"key20240829104515_B45","doi-asserted-by":"crossref","first-page":"105569","DOI":"10.1016\/j.isci.2022.105569","article-title":"Hepatocyte-derived GDF15 suppresses feeding and improves insulin sensitivity in obese mice","volume":"25","author":"Xie","year":"2022","unstructured":"45. Xie B, Murali A, Vandevender A, Chen J, Silva A, Mello F, et al. Hepatocyte-derived GDF15 suppresses feeding and improves insulin sensitivity in obese mice. iScience. 2022;25(12):105569. doi: 10.1016\/j.isci.2022.105569.","journal-title":"iScience"},{"issue":"19","key":"key20240829104515_B46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197214","article-title":"Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy","volume":"21","author":"Kralisch","year":"2020","unstructured":"46. Kralisch S, Hoffmann A, Estrada-Kunz J, Stumvoll M, Fasshauer M, T\u00f6njes A, et al. Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy. Int J Mol Sci. 2020;21(19):7214. doi: 10.3390\/ijms21197214.","journal-title":"Int J Mol Sci"},{"key":"key20240829104515_B47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106578","article-title":"A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects","volume":"187","author":"Aguilar-Recarte","year":"2023","unstructured":"47. Aguilar-Recarte D, Barroso E, Zhang M, Rada P, Pizarro-Delgado J, Pe\u00f1a L, et al. A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects. Pharmacol Res. 2023;187:106578. doi: 10.1016\/j.phrs.2022.106578.","journal-title":"Pharmacol Res"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:24:04Z","timestamp":1724945044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/gdf-15-levels-in-patients-with-polycystic-ovary-syndrome-treated-with-metformin-a-combined-clinical-and-in-silico-pathway-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":47,"alternative-id":["10.20945\/2359-4292-2023-0416"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0416","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e230416"}}